论文部分内容阅读
探讨利培酮、喹硫平和齐拉西酮对首发女性精神分裂症妊娠患者糖脂代谢及妊娠结局的影响。选取2012年7月~2014年7月我院收治的首发精神分裂症孕妇97例作为研究对象,根据治疗方案分为利培酮组(27例)、喹硫平组(36例)、齐拉西酮组(34例),均治疗8周。记录临床疗效、不良用药反应和不良妊娠结局,治疗前后采用阳性和阴性综合征量表(PANSS)、简明精神病量表(BPRS)检测精神分裂症严重程度,检测治疗前后体质量(BMI)及糖脂水平。结果发现,3组患者临床疗效、妊娠结局、不良用药反应比较无明显差异(p>0.05),3组治疗后PANSS、BPRS评分均下降,差异具有统计学意义(p<0.05),但3组治疗后组间比较无差异(p>0.05);3组患者治疗前后空腹血糖(FPG)、餐后2 h血糖(2h PBG)、胆固醇(TC)无明显变化(p>0.05);3组治疗后BMI、血清胰岛素(FINS)、甘油三酯(TG)均有所改变,同组治疗前后差异显著(p<0.05);其中喹硫平组BMI上升幅度较齐拉西酮组明显(p<0.05),利培酮组FINS下降,喹硫平组、齐拉西酮组均上升,利培酮组FINS低于喹硫平组、齐拉西酮组,差异有统计学意义(p<0.05)。因此,利培酮、喹硫平、齐拉西酮对首发女性精神分裂症孕妇的精神分裂症状改善疗效一致,但易致糖脂代谢紊乱,存在一定风险。
To investigate the effects of risperidone, quetiapine and ziprasidone on glucose and lipid metabolism and pregnancy outcomes in first-episode female schizophrenia. Ninety-seven first-episode schizophrenia patients admitted to our hospital from July 2012 to July 2014 were selected as study subjects, and were divided into risperidone group (n = 27), quetiapine group (n = 36) Westernization group (34 cases), were treated for 8 weeks. The clinical efficacy, adverse drug reactions and adverse pregnancy outcomes were recorded. Before and after treatment, the positive and negative syndrome scales (PANSS) and the Simple Mental Illness Scale (BPRS) were used to detect the severity of schizophrenia. The body mass index (BMI) Lipid level. The results showed that there was no significant difference in clinical efficacy, pregnancy outcome and adverse drug reaction between the three groups (p> 0.05). The PANSS and BPRS scores of the three groups decreased after treatment, the difference was statistically significant (p <0.05) The levels of fasting blood glucose (FPG), postprandial 2h PBG and cholesterol (TC) had no significant change in three groups (p> 0.05) after treatment. There was no significant difference between the three groups (P <0.05). The BMI in quetiapine group was significantly higher than that in ziprasidone group (p <0.05). The BMI, serum insulin and triglyceride were all changed after treatment in the same group 0.05). The FINS of risperidone group decreased, while that of quetiapine group and ziprasidone group increased. The FINS of risperidone group was lower than that of quetiapine group and ziprasidone group (p <0.05) ). Therefore, risperidone, quetiapine, ziprasidone on first-episode schizophrenia in women with schizophrenia to improve the efficacy of the same, but easy to cause glucose and lipid disorders, there is a certain risk.